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The levels of cell free circulating tumor DNA (ctDNA) in plasma cor-relate with treatment response and outcome in systemic lym-phomas. Notably, in brain tumors, the levels of ctDNA in the cere-
brospinal fluid (CSF) are higher than in plasma. Nevertheless, their role in
central nervous system (CNS) lymphomas remains elusive. We evaluated
the CSF and plasma from 19 patients: 6 restricted CNS lymphomas, 1 sys-
temic and CNS lymphoma, and 12 systemic lymphomas. We performed
whole exome sequencing or targeted sequencing to identify somatic muta-
tions of the primary tumor, then variant-specific droplet digital polymerase
chain reaction was designed for each mutation. At time of enrollment, we
found ctDNA in the CSF of all patients with restricted CNS lymphoma but
not in patients with systemic lymphoma without CNS involvement.
Conversely, plasma ctDNA was detected in only 2 out of 6 patients with
restricted CNS lymphoma with lower variant allele frequencies than CSF
ctDNA. Moreover, we detected CSF ctDNA in one patient with CNS lym-
phoma in complete remission and in one patient with systemic lymphoma,
3 and 8 months before CNS relapse was confirmed, indicating that CSF
ctDNA might detect CNS relapse earlier than conventional methods.
Finally, in two cases with CNS lymphoma, CSF ctDNA was still detected
after treatment even though no tumoral cells were observed by flow
cytometry (FC), indicating that CSF ctDNA detected residual disease better
than FC. In conclusion, CSF ctDNA can detect CNS lesions better than plas-
ma ctDNA and FC. In addition, CSF ctDNA predicted CNS relapse in CNS
and systemic lymphomas. 
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ABSTRACT
Introduction
Central nervous system (CNS) involvement in B-cell malignancies is associated
with dismal prognosis, especially in the relapse setting.1 Primary central nervous sys-
tem lymphoma (PCNSL) is defined by the presence of CNS lymphoma in the
absence of systemic disease.2 Conversely, secondary involvement of the CNS
(SCNSL) is characterized by CNS infiltration with concomitant or previous history of
systemic lymphoma.3 The diagnosis of CNS lymphoma is commonly based on cra-
nial magnetic resonance imaging (MRI) along with brain
excisional biopsy or analysis of  cerebrospinal fluid (CSF) or
vitreous fluid.4 In some cases, biopsies can be challenging
owing to the difficulty in accessing the tumor and the inher-
ent risks associated with cranial surgery. 
Patients with aggressive systemic lymphomas and risk
factors for CNS relapse are routinely monitored by cytol-
ogy and flow cytometry (FC) analysis of CSF. Cytology is
highly specific but has a very limited sensitivity, showing
up to 40% false negatives. In contrast, FC is more sensitive,
detecting malignant cells in up to 5-15% of patients with
negative cytology.5,6 However, FC still has some limitations,
and in a relevant fraction of patients, recurrence in the CNS
is found shortly after a negative result by FC, suggesting
that tumor cells were undetected. 
Several studies have demonstrated that cell free circulat-
ing tumor DNA (ctDNA) can be detected in plasma from
patients with B-cell lymphomas and correlates with meta-
bolic tumor volume and outcome.7,8 Due to the difficulties
in the diagnosis of brain tumors, there is growing interest in
the analysis of ctDNA in plasma and CSF and their poten-
tial utility in the management of these patients. Thus, we
and others have explored the analysis of CSF in solid brain
tumors as a better source of ctDNA compared with
plasma.9-12 As per B-cell lymphomas, only a minority of
patients with restricted CNS lymphomas present detectable
ctDNA in plasma13,14 and only a few studies of ctDNA in
CSF have been performed so far.15-19 In this regard, the
MYD88 L265P mutation has been identified in the CSF
ctDNA from some patients with PCNSL and lymphoplas-
macytic lymphoma with CNS involvement.17-19 More
recently, a different study using a next-generation sequenc-
ing (NGS)-based assay, detected at least one tumor-derived
genetic alteration in the CSF from eight patients with
relapsed CNS lymphoma and demonstrated that CSF
ctDNA levels correlated with treatment response.15
Taken together, these studies demonstrate that CSF
ctDNA could be detected in patients with CNS lymphomas
and could be useful to monitor the disease, but a thorough
analysis of its relevance on the diagnosis and monitoring of
the disease is still needed. 
Here, we conducted a study to explore whether the
analysis of ctDNA in the CSF and plasma could be useful to
complement the diagnosis and molecular profile of tumors,
as well as to monitor treatment response in CNS lym-
phomas. In addition, we evaluated whether the presence of
CSF ctDNA in patients with systemic lymphoma could be
more sensitive to detect CNS malignancies than CSF stan-
dard analyses and plasma ctDNA.
Methods
Patients and samples
Nineteen patients diagnosed with the following conditions
were included: restricted CNS lymphomas, n=6; PCNSL, n=1;
SCNSL, n=5; systemic lymphoma with concomitant CNS involve-
ment, n=1; and systemic lymphoma without CNS disease but risk
factors for CNS relapse, n=12. Risk factors for CNS relapse were
defined as: diffuse large B-cell lymphoma (DLBCL) with testis,
kidney or adrenal involvement; DLBCL with involvement of two
or more extranodal sites along with high lactate dehydrogenase;
high-grade B-cell lymphoma (HGBCL) with MYC and/or BCL2
rearrangements or Burkitt lymphoma. All patients were diagnosed
and treated at Vall d’Hebron University Hospital (Barcelona,
Spain). Diagnosis of CNS disease was established by MRI imaging
and tumor biopsy in cases with parenchymal involvement, or by
FC and cytology in cases with leptomeningeal disease. 
A written informed consent was obtained from all individuals
in accordance with the Declaration of Helsinki and the study was
approved by the local clinical research ethics committee. As part
of standard of care practice, in patients with systemic lymphoma
and risk factors for CNS relapse, prophylactic intrathecal (IT)
methotrexate (MTX) was administered every 3 weeks together
with systemic chemotherapy. In addition, in cases with lep-
tomeningeal disease, IT chemotherapy was administrated every
3-4 days until malignant cells were not detected by FC. CSF (1-2
mL) and plasma were collected before treatment in all patients and
sequentially in patients who received IT chemotherapy as part of
routine practice. Cytology and FC were performed in all CSF sam-
ples. Two out of 7 patients with CNS lymphoma and 3 out of 12
with systemic lymphoma received steroids before the baseline
CSF sample. Evaluation of response was assessed at the end of
treatment and/or on suspicion of disease progression by using
MRI imaging in cases with CNS parenchymal involvement and by
CSF analysis (FC and cytology) in patients with leptomeningeal
disease. Positron emission tomography/computed tomography
(PET/CT) was used to assess response at the end of treatment in
patients with systemic lymphoma. 
Sample collection and DNA extraction
The median volume of plasma and CSF obtained was 2.5 mL
(range: 1-6) and 1 mL (range: 0.3-2), respectively. Peripheral blood
was collected in tubes containing K2EDTA (Vacutainer) and cen-
trifuged at 1600xg for 10 minutes (min). The plasma was then
transferred to another tube that was further centrifuged at 3000xg
for 5 min. CSF samples were centrifuged at 3000xg for 5 min. The
supernatant was collected and CSF-derived and plasma-derived
circulating cell free DNA (cfDNA) was extracted using the
QIAamp Circulating Nucleid Acids kit and quantified using a flu-
orimeter. DNA was extracted from formalin-fixed paraffin-
embedded tumor samples using the QIAamp DNA FFPE tissue kit.
Germline DNA was extracted from peripheral blood granulocytes
using the Qiagen DNeasy Blood and Tissue kit. 
DNA sequencing and mutation genomic analysis
We performed DNA sequencing of the tumors of 16 out of 19
patients: 11 of 16 were sequenced using a 300 gene targeted NGS
panel (Vall d’Hebron Institute of Oncology, Genomics Facility) and
in the remaining five, whole-exome DNA sequencing (WES) was
performed in both the tumor and germline DNA. SureSelect
Human All Exon V5 (Agilent Technologies) was used to perform
whole exome enrichment for the Illumina paired-read sequencing
platform HiSeq2500 with a read length of 2x100bp (Online
Supplementary Appendix). The amount of DNA used for NGS panel
and WES was 1 mg and 0.4-4 mg, respectively.  In 3 out of 19
patients (NHL1, NHL4 and NHL5), MYD88 L265P mutation was
detected in the tumor by routine genomic analysis performed at
diagnosis, therefore tumor DNA sequencing was not performed.
Droplet digital polymerase chain reaction and 
quantification of circulating tumor-specific DNA
Given the limited amount of cfDNA available, ddPCR was per-
formed to determine the presence of ctDNA mutations in the CSF
and plasma, ensuring sensitivity and precision. A set of driver
mutations along with additional mutations not predicted as driv-
ers by Cancer Genome Interpreter (CGI), but relevant according to
expert knowledge, were selected for further validation by ddPCR. 
Custom Taqman SNP genotyping assays for ddPCR were
designed to specifically detect the selected point mutations and
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the corresponding wild-type alleles. Genomic DNA from tumor
tissues (10 ng), germline DNA from peripheral blood granulocytes
(10 ng), plasma DNA, and CSF DNA (1-5 ng) were used for ddPCR
analysis using the QX200 Droplet Digital PCR system according
to manufacturer's protocols and the literature.20  
Results
Circulating tumor DNA in the cerebrospinal fluid of
patients with central nervous system restricted B-cell
lymphoma is more abundant than in plasma
Here, we sought to analyze the presence of ctDNA in the
CSF and plasma from 19 patients with B-cell lymphomas
with and without CNS disease at time of enrollment (Table
1). Six patients exhibited CNS restricted disease, one sys-
temic and CNS disease, and 12 systemic disease with no
CNS involvement. CSF was obtained at the same time as
plasma in all patients. WES or targeted sequencing of the
tumors was performed to identify somatic mutations
(Figure 1). Variant-specific ddPCR detecting 1-5 variants per
patient was performed to detect ctDNA. 
To demonstrate that the variant-specific ddPCR was
highly specific, we performed MYD88 L265P ddPCR in ten
CSF samples obtained from patients with hydrocephalus
without a brain tumor (n=6), and from patients diagnosed
with glioma (n=3) and a cavernoma (n=1). No mutant allele
was found in any of the cases. 
Analysis of the ctDNA in the CSF and plasma of the six
CNS restricted lymphomas showed detectable ctDNA at
high variant allele frequency (VAF)  (ranging from 1% to
95%) in all cases. In contrast, ctDNA in plasma was only
detected in 2 out of 6 cases at very low VAF (always <5%)
(Table 1), highlighting that in CNS restricted lymphomas,
ctDNA in cerebrospinal fluid of patients with CNS lymphoma
haematologica | 2021; 106(2) 515
Figure 1. Genomic landscape of the cohort of study. (A) Pie chart representing the proportion of samples of each lymphoma type (see color legend). Two sectors in
each sample depict whether the patient had systemic (gray) or central nervous system (CNS) restricted disease (black). (B) Circus plot representing all mutations
identified across 16 lymphoma patients. A mutation was defined as driver according to Cancer Genome Interpreter (see Online Supplementary Appendix) colored in
red (see Methods section). Genes with recurrent mutations have been highlighted in bold. (C) Bubble plot representing all driver mutations and droplet digital
polymerase chain reaction (ddPCR) validated mutations identified in each patient. The bubble size represents the cancer allelic fraction (CAF) (see Online
Supplementary Appendix) and the border has been highlighted in black if it has been found by ddPCR, in either the cerebrospinal fluid or plasma of each patient.
NHL: non-Hodgkin lymphoma; DLBCL: diffuse large B-cell lymphoma; HGBCL: high-grade B-cell lymphoma; WM: Waldeström macroglobulinemia; MCL: mantle cell
lymphoma; BL: Burkitt lymphoma.
   A                                                                     B
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Table 1. Patients’ characteristics and tumor mutations at the time of enrolment and outcome. 
ID             Age       Histol        Dx      Disease       Systemic    CNS       CNS     Tumor         Tumor                      VAF        VAF        VAF          Outcome
                                                          status              inv          inv      (FC/C)      seq           mutations               tumor      CSF      plasma
CNS lymphoma
   NHL1          59         DLBCL    PCNSL    New dx                No              P             -/-              -                MYD88 L265P                -            48%            N                    CR
   NHL2          60         DLBCL    SCNSL   Relapse               No          P, LM         +/-          WES             CD79B Y197D              17%           9%             -                    CR
                                                                                                                                                                           MYD88 L265P              22%          25%            -
                                                                                                                                                                           FOXO1 D69A                13%            -              -
                                                                                                                                                                           TMSB4A Q24P             54%          20%            -                       
   NHL3          53         DLBCL    SCNSL   Relapse               No          P, LM        +/+        Panel            B2MM1T                      41%            N              N               PD, died
                                                                                                                                                                           BCOR N145S               68%          52%            N
                                                                                                                                                                           CREBBP R1664C         21%            N              N                      
   NHL4          75           WM       SCNSL   Relapse               No            LM          +/+            -                MYD88 L265P                -            33%            N                    CR
   NHL5          58         DLBCL    SCNSL   Relapse               No          P, LM        +/+            -                MYD88 L265P              86%          29%           5%      CR, CNS relapse
                                                                                                                                                                                                                                                                                
   NHL6          73           MCL      SCNSL   Relapse               No            LM          +/+        Panel            ATM H2872L                31%          34%           2%             PD, died
                                                                                                                                                                           MEF2B K23R               90%          95%           4%
CNS and systemic lymphoma
   NHL7          72           MCL      SCNSL   Relapse               LN            LM          +/+        Panel            BRAF N581S                44%            N             7%             PD, died
Systemic lymphoma
   NHL8          50        HGBCL         -         New dx                LN,           No            -/-           WES             MYC Y27C                    28%            N            16%                  CR
                                                                                                 bone,                                                               ARID1A E1104             32%            N            20%
                                                                                              intestine                                                            MEF2B D83G               33%            N            18%
                                                                                                                                                                           MLL2 C533fs                50%            N            31%
                                                                                                                                                                           CCND3 P284fs             29%            N            16%                    
   NHL9          38        HGBCL         -         New dx                LN,           No            -/-           WES             ID3 Y48*                       38%            N            12%                  CR
                                                                                              intestine                                                            DDX3X Q360fs            98%            N            15%                    
   NHL10        73         DLBCL         -         New dx                LN,           No            -/-          Panel            MLL2 splicing              60%            N            19%                  CR
                                                                                                kidney                                                              MLL2 P3139A               34%            N            12%                    
   NHL11        72         DLBCL         -         New dx           LN, lung,      No            -/-          Panel            TP53 R273C                  32%            N            12%                  CR
                                                                                                 ileum                                                               CREBBP Y145C           25%            N            27%                    
   NHL12        86         DLBCL         -         New dx         LN, breast     No            -/-          Panel            MCL1 L186F                 31%            N           0.9%                 CR
                                                                                                                                                                           PTNPN6 T80fs             26%            N              N                      
   NHL13        77         DLBCL         -         New dx                LN,           No            -/-           WES             MYD88 L265P              29%            N             5%                   CR
                                                                                                testes                                                               PIM1 L2F                      27%            N             3%                     
                                                                                                                                                                           MEF2B E77K               27%            N             5%                     
   NHL14        62         DLBCL         -         New dx              Teste          No            -/-          Panel            HSD3B2 L108W           22%            N              N                    CR
                                                                                                                                                                           MYD88 L265P              31%            N              N                      
   NHL15        75         DLBCL         -         New dx         LN, testes,    No            -/-          Panel            BCOR S1517fs             63%            N              N                    CR
                                                                                          liver, adrenal                                                        EZH2 P557L                 34%            N              N                      
   
   NHL16†      57         DLBCL         -         New dx         LN, sinus,     No            -/-          Panel            MYD88 V217F              28%            N              N       CR, CNS relapse
                                                                                                bones                                                               ASXL2 K927R               42%            N              N                      
   NHL17        58        HGBCL         -         New dx                LN            No            -/-          Panel            CREBBP S1436I           50%            N            16%     CR, CNS relapse
                                                                                                                                                                                                                                                                                
   NHL18†      60             BL             -         New dx                LN,           No            -/-           WES             ID3 L54V                       37%            N              N                    CR
                                                                                              intestine                                                            KRAS G12V                   34%            N             1%
                                                                                                                                                                           TCF3 D561E                 42%            N              N
                                                                                                                                                                           ABL1 G321R                 43%            N           0.5%                    
   NHL19†      65             BL             -         New dx          LN, bone      No            -/-          Panel            ARID1A del                   9%             N             1%                   CR
BL: Burkitt lymphoma; C: cytology; CNS: central nervous system; CR: complete response; CSF: cerebrospinal fluid; DLBCL: diffuse large B-cell lymphoma;  Dx: diagnosis; FC: flow
cytometry; HGBCL: high-grade B-cell lymphoma;  Histol: histology; ID: patient identification number; inv: involvement; LM: leptomeningeal; LN: lymph nodes; MCL: mantle cell
lymphoma; N: not detectable; Neg: negative; NHL: non-Hodgkin lymphoma;  P: parenchyma; PCNSL: primary central nervous system lymphoma; PD: progressive disease; Pos: pos-
itive; SCNSL: secondary central nervous system lymphoma; seq: sequencing;  VAF: variant allele frequency; WES: whole exome sequencing; WM: Waldeström macroglobulinemia.
†Plasma samples were collected after administration of systemic chemotherapy. 
ctDNA in cerebrospinal fluid of patients with CNS lymphoma
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Figure 2.  Levels of circulating tumor DNA (ctDNA) correlate
with disease progression and response to treatment in B-
cell lymphomas. (A-F) Longitudinal monitoring of two
patients with central nervous system (CNS) lymphomas
(NHL2 and NHL4) and (G-L) six patients with systemic lym-
phomas with no evidence of CNS disease (NHL8, NHL9,
NHL10, NHL13, NHL18, and NHL19) through (A) cere-
brospinal fluid (CSF) and (D, G and J) plasma ctDNA analysis
(variant allele frequency [VAF] values for each mutation
detected using droplet digital polymerase chain reaction
[ddPCR]) and its correlation with (B) CSF flow cytometry
(cells/µL), (C) cytology (+/- presence/absence of cells), and
(F, I and L) radiological imaging  (magnetic resonance imag-
ing [MRI] and positron emission tomography/computed
tomography scans). Data points are vertically aligned (E, H
and K). Clinical information for each patient includes type of
treatment and radiological response assessment. MRI
scans for patient NHL4 are not shown given that the patient
only presented leptomeningeal involvement. Dx: time of
diagnosis; IT MTX: intrathecal methotrexate; R-CHOP: com-
bined therapy (rituximab, cyclophosphamide, doxorubicin
hydrochloride, vincristine and prednisolone); Burk:
Burkimab regimen; CR: complete response; EOT: end of













ctDNA is better identified in the CSF than in plasma.
Interestingly, these two cases with restricted CNS lym-
phoma in which plasma ctDNA was detected had a previ-
ous history of systemic disease. This finding might reveal a
systemic nature of some restricted SCNSL and deserves fur-
ther investigation in larger studies.
We then analyzed 12 patients with systemic lymphoma
without CNS involvement but with high risk for CNS
relapse. In these cases, lumbar puncture was performed to
rule out CNS infiltration and to administer IT MTX. As
opposed to cases with CNS involvement, no ctDNA was
detected in the CSF while it was detected at high VAF in the
plasma of the majority of cases (Table 1). Finally, the patient
with systemic and concomitant CNS disease had ctDNA in
plasma but not in the CSF, suggesting that some CNS
lesions cannot be captured through CSF ctDNA. 
Central nervous system circulating tumor DNA exhibits
higher sensitivity than flow cytometry in detecting 
central nervous system lesions
We next correlated the detection of ctDNA with the iden-
tification of malignant cells by conventional tests in the
same CSF samples at time of enrollment. Cytology detected
the presence of malignant cells in 4 out of 6 CNS restricted
lymphomas. In these four cases the FC analysis also detect-
ed lymphoma cells. In one case (NHL2), cytology was nor-
mal but a small amount of tumor cells was observed by FC
(0.06 cell/mL). Notably, all six cases exhibited CSF ctDNA.
Importantly, in a patient with newly diagnosed PCNSL
(NHL1) we could not detect lymphoma cells by FC or cytol-
ogy; however, ctDNA was abundantly found in the CSF
(Table 1). These results indicate that ctDNA analysis of the
CSF can improve the detection of CNS lymphoma by con-
ventional techniques.
Cerebrospinal fluid circulating tumor DNA can be used
to monitor central nervous system tumor burden and
response to treatment 
To address whether the amount of CSF ctDNA could be
useful to monitor tumor burden in CNS lymphomas, we
analyzed sequential concomitant samples of CSF and plas-
ma. CSF was obtained as part of the standard procedures
before each administration of IT MTX or on suspicion of
relapse. Tumor burden was evaluated by MRI and/or FC
depending on the lymphoma location. We observed that
CSF ctDNA levels correlated with disease response and
progression (Figure 2). In addition, tumor burden measured
by MRI and FC was concordant with CSF ctDNA levels in
two patients with CNS lymphoma (Figure 2). Importantly,
plasma ctDNA levels remained constantly low (VAF <6%)
S. Bobillo et al.
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Figure 3. Cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) is more sensitive than flow cytometry (FC) to detect central nervous system (CNS) relapse and
residual disease in CNS-restricted lymphomas. Longitudinal monitoring of three patients with CNS-restricted lymphomas (NHL3, NHL5 and NHL6) through (A) CSF
and (D) plasma ctDNA analysis (variant allele frequency [VAF] values for each mutation obtained by droplet digital polymerase chain reaction [ddPCR]) and its corre-
lation with (B) CSF flow cytometry (cells/mL), (C) cytology (+/- presence/absence of cells). (E) Type of treatment and response assessment, (F) radiological imaging
(MRI). Data points are vertically aligned. MRI scans for patient NHL6 and NHL5 are not shown given that the patient only presented leptomeningeal involvement at
diagnosis. Dx: time of diagnosis; IT MTX: intrathecal methotrexate; BAM-R: combined therapy (rituximab, carmustine, cytarabine and methotrexate); ASCT: autologous








in sequential samples and did not correlate with the disease
status, underlining the fact that plasma ctDNA is not useful
to monitor the activity of CNS restricted lymphomas
(Figure 2).
Six patients with systemic lymphoma without CNS
involvement had sequential plasma samples collected at the
same time as CSF. We observed that plasma ctDNA became
undetectable after the first cycle of treatment in all cases, in
agreement with PET/CT results (Figure 2), suggesting that
plasma ctDNA is a good tool to monitor response to treat-
ment in these patients. 
Cerebrospinal fluid circulating tumor DNA can identify
central nervous system relapse and residual central
nervous system disease better than flow cytometry
We then addressed whether the presence of ctDNA in
the CSF could be more sensitive than conventional CSF
analyses to monitor CNS lymphoma and detect CNS
relapse.
In two cases of CNS lymphoma (NHL3 and NHL5), we
observed that CSF ctDNA levels increased earlier than the
detection of cells by FC. In NHL3, after the first dose of IT
MTX, despite the fact that the patient did not exhibit a
complete neurological response, we observed a sharp
decrease in CSF ctDNA levels concomitant with a decrease
in the tumor cells by FC. However, after three doses of IT
MTX, although FC was negative, a clear ctDNA increase
was observed. The patient died 1 month later due to pro-
gression (Figure 3). In NHL5, CSF ctDNA levels also
decreased with response to treatment and remained unde-
tectable after complete remission. However, CSF ctDNA
reappeared in two CSF samples collected 2 and 4 months
ctDNA in cerebrospinal fluid of patients with CNS lymphoma







Figure 4. Cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) detects central nervous system (CNS) involvement and residual disease in patients with systemic
lymphoma and is more sensitive than conventional tests. Longitudinal analyses of (A) CSF and (D) plasma ctDNA (VAF values for each mutation detected using
ddPCR) and correlation with (B) CSF FC (cells/mL), (C) cytology (+/- presence/absence of cells), and (E) type of treatment and radiological response assessment. (F)
Radiological imaging (magnetic resonance imaging [MRI] and positron emission tomography/computed tomography scans) in two patients with systemic lymphoma
(NHL16 and NHL17) that present CNS relapse. Data points are vertically aligned. MRI scans for patient NHL17 are not shown given that the patient only presented
leptomeningeal involvement. Dx: time of diagnosis; R-CHOP: combined therapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone); IT MTX:
intrathecal methotrexate; CR: complete response; P: parenchymal; LM: leptomeningeal; EOT: end of treatment; m: month; d: days; NA: not available. *CSF sample
was not available for ctDNA analyses 
after treatment due to the presence of minimal neurological
symptoms, when brain-spinal MRI and CSF FC did not
show any evidence of disease; 8 months later CNS relapse
was confirmed (Figure 3). Taken together, our results indi-
cate that ctDNA can be a more sensitive tool than FC to
monitor relapse of CNS lymphomas.
In one additional case of CNS lymphoma (NHL6) treat-
ment with IT MTX decreased the number of cells in the
CSF till they were no longer detectable by FC. However,
CSF ctDNA was still detectable. Notably, this patient
relapsed shortly after the analysis (Figure 3). In a similar
way, we found persistence of ctDNA in the CSF from case
NHL17 after treatment for CNS relapse, despite the fact
that FC did not detect malignant cells. Four months later,
the patient relapsed. (Figure 4). These results point out
that the detection of CSF ctDNA may help to identify
patients with residual disease who are likely to relapse.
A subset of patients with systemic lymphoma presents
high risk of CNS relapse, which frequently occurs during
treatment or shortly thereafter. To address whether the
presence of CSF ctDNA could be more sensitive than FC
to detect CNS disease, we analyzed sequential CSF sam-
ples from eight patients with systemic lymphoma
obtained while receiving prophylactic IT MTX. Two out
of 8 patients relapsed in the CNS during the time of study
(Figure 4). In one case (NHL17), we found CSF ctDNA at
the same moment in which FC showed a positive result.
However, we could not detect ctDNA in the CSF samples
collected 9 and 7 months before CNS progression.
Notably, in case NHL16, the detection of ctDNA in the
CSF with a VAF of 7% antedated by 3 months the CNS
relapse. Importantly, at the time of ctDNA detection, the
patient was asymptomatic and CSF FC was normal
(Figure 4). This case points out that CSF ctDNA could
detect CNS involvement in systemic lymphomas earlier
than standard procedures. Finally, in the remaining six
patients with systemic lymphoma and sequential CSF
samples, ctDNA was not detected and, with a median fol-
low-up of 18 months (range: 12-28 months), these patients
did not develop CNS disease.
Discussion
The diagnosis and monitoring of CNS lymphoma are
still challenging. MRI can be misleading and not suffi-
ciently sensitive, and the difficulties of the intracranial
tumor biopsies challenge histological diagnosis.
Mutational analysis of the CSF could be useful in these
cases, since the presence of MYD88 L265P mutation
strongly suggests the diagnosis of PCNSL.13,14,16-18 Ours is a
proof of concept study aiming to identify and character-
ize ctDNA in the CSF of patients with CNS lymphoma
and to evaluate its role in the management of these
patients. We were able to identify ctDNA in the CSF from
all patients with restricted CNS disease and show that
CSF ctDNA could complement the diagnosis, identify
somatic mutations, monitor tumor burden and response
to treatment, and facilitate early detection of relapse, as
well as detect residual disease after treatment. In addi-
tion, our results support the notion that the CSF is a bet-
ter source of ctDNA than plasma. 
Assessment of therapeutic response in CNS lym-
phomas is usually performed by brain MRI along with FC
and cytology. Regrettably, around 50-60% of patients
with CNS lymphoma will eventually relapse.21 Notably,
we observed that CSF ctDNA was able to detect CNS
lesions better than FC and cytology. In addition, CSF
ctDNA was able to predict CNS relapse months before
MRI or FC, indicating that it can be used for early detec-
tion of tumor relapse. 
CNS relapse from systemic lymphoma is a fatal compli-
cation with an overall survival of less than 6 months, and
early identification of patients with CNS relapse is of para-
mount value.3 High-risk patients are usually tested for CNS
disease by CSF analysis including cytology and FC.
Although FC is a more sensitive test than conventional
cytology,5,6 it has some limitations22 and some patients with
no evidence of CNS disease by FC still relapse, suggesting
the presence of undetected malignant cells in the CSF. We
identified ctDNA in the CSF in the absence of MRI or FC
detection earlier than CNS relapse. This indicates that CSF
ctDNA could facilitate early detection of CNS relapse in
high-risk systemic lymphomas who undergo serial lumbar
punctures to administrate prophylactic IT chemotherapy,
therefore improving management of these patients. 
Moreover, we observed the persistence of high levels of
CSF ctDNA in some patients even though FC did not
detect tumor cells. This suggested that the detection of a
residual disease by CSF ctDNA could be used to deter-
mine the type and duration of treatments. 
Taken together, and with the limitation of the reduced
number of patients analyzed, our findings show that CSF
ctDNA can be an important tool to complement standard
procedures to evaluate the CNS lymphoma disease sta-
tus. This technology can be exploited as a 'liquid biopsy'
of CNS lymphoma opening a novel way forward for
research in circulating biomarkers of CNS lymphoma
with an important impact on the future characterization,
diagnosis, prognosis, and management of this type of dis-
eases.
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